

Effect of tomato consumption on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials

by Mohammad Rudiansyah

Submission date: 13-Jun-2022 10:06AM (UTC-0400)

Submission ID: 1856069572

File name: of_tomato_consumption_on_inflammatory_markers_in_health_and.pdf (1,006.28K)

Word count: 5500

Character count: 30060



Contents lists available at ScienceDirect

Clinical Nutrition ESPEN

journal homepage: <http://www.clinicalnutritionespen.com>

Meta-analysis

Effect of tomato consumption on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials

Gunawan Widjaja^{a, b, *}, Rumi iqbal doewes^c, Mohammad Rudiansyah^d,
Mohammed Q. Sultan^e, Mohammad Javed Ansari^{f, **}, Samar Emad Izzat^g,
Mohanad S. Al Jaber^h, Hamzah H. Kzarⁱ, Yasser Fakri Mustafa^j, Ali Thaeer Hammid^k,
Abduladheem Turki Jalil^l, Surendar Aravindhana^m

^a Universitas Krisnadwipayana, Jatiwaringin, Indonesia^b Faculty of Public Health, Universitas Indonesia, Depok, Indonesia^c Faculty of Sport, Universitas Sebelas Maret, Jl. Ir. Sutami, 36A, Kentingan, Surakarta, Indonesia^d Division of Nephrology & Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat / Ulin Hospital, Banjarmasin, Indonesia^e College of Dentistry, Al-Ayen University, Thi-Qar, Iraq^f Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, Saudi Arabia^g Al-Nisour University College, Baghdad, Iraq^h Al-Manara College for Medical Sciences, Maysan, Iraqⁱ Veterinary Medicine College, Al-Qasim Green University, Al-Qasim, Iraq^j Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul-41001, Iraq^k Computer Engineering Department, Imam Ja'afar Al-Sadiq University, Baghdad, Iraq^l Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq^m Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India

ARTICLE INFO

Article history:

Received 28 February 2022

Accepted 18 April 2022

Keywords:

Tomato

Inflammation

C-Reactive protein

Interleukin 6

Tumor necrosis factor- α

Meta-analysis

SUMMARY

Background and aims: Inflammation is a major cause of chronic diseases. Several studies have investigated the effects of tomato intake on inflammatory biomarkers; however, the results are equivocal. Therefore, the present study aimed to systematically review and analyses randomized clinical trials (RCTs) assessing the effects of tomato intake on inflammatory biomarkers in adults.

Methods: A systematic search was performed in PubMed, Scopus, ISI Web of Science, and Cochrane Library databases to find RCTs related to the effect of tomato intake on inflammatory markers, including C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor- α (TNF- α), up to November 2021. Meta-analyses were performed using the random-effects model.

Results: A total of 465 subjects sourced from seven eligible RCTs (8 treatment arms) were entered into the analysis. Pooled effect size of articles indicated that tomato intake was not significantly effective on CRP (WMD: 0.13 mg/dL, 95% CI: -0.09 to 0.36; $P = 0.23$, $I^2: 83.9\%$) and IL-6 (Hedges' $g = -0.12$; 95% CI -0.36, 0.13; $P = 0.34$, $I^2: 0.0\%$) levels compared to the control group. But it can significantly reduce TNF- α (Hedges' $g = -0.45$; 95% CI -0.76, -0.13; $P = 0.005$, $I^2: 0.0\%$) levels.

Conclusion: Generally, the present study showed that tomato intake has no significant effect on serum CRP, and IL-6 concentrations, but can reduce serum TNF- α levels significantly. However, additional well-designed studies that include more diverse populations and longer duration are warranted.

© 2022 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

1. Introduction

Inflammatory responses are protective biological processes to eliminate detrimental stimuli by coordination of pro and anti-inflammatory endogenous mediators [1]. Inflammation can be both acute and chronic [2]. Chronic inflammation, which is

* Corresponding author. Universitas Krisnadwipayana, Bekasi, Indonesia.

** Corresponding author. Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, Saudi Arabia.

E-mail addresses: widjaja_gunawan@yahoo.com (G. Widjaja), javedpharma@gmail.com (M.J. Ansari).

<https://doi.org/10.1016/j.clnesp.2022.04.019>

2405-4577/© 2022 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

Please cite this article as: G. Widjaja, R. doewes, M. Rudiansyah *et al.*, Effect of tomato consumption on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials, Clinical Nutrition ESPEN, <https://doi.org/10.1016/j.clnesp.2022.04.019>

reflected by the enhancement of cytokines, markers of endothelial activation, and acute-phase protein synthesis, is recognized as a major contributor to the development of non-communicable diseases, including cardiovascular diseases (CVDs), type 2 diabetes (T2DM), neurological disorders, pulmonary diseases, autoimmune disorders and most types of cancers [3–7]. C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor- α (TNF- α) are the most important inflammatory mediators concerning health status which are secreted by adipocytes and are increasingly considered indicators of chronic inflammation [8,9]. The concentration of these inflammatory mediators can be influenced by various factors such as disease development, age, smoking, and specific nutrients [10,11]. Different therapeutic strategies such as medication and lifestyle modifications have been applied to reduce inflammatory responses [12,13]. Recent studies have reported that the administration of anti-inflammatory drugs has adverse effects ranging from minor symptoms such as digestive problems to serious disorders like liver-kidney disorders [14,15]. So recently researchers have focused on dietary interventions, as a cheap strategy with few side effects, to reduce inflammation in humans.

Evidence suggests that greater consumption of fruit and vegetables can effectively reduce inflammation and oxidative stress [16,17]. Tomato, otherwise referred to as *Solanum lycopersicum*, is ubiquitous in most dietary patterns across the world and its contribution to health has been reported in scientific research [18]. It can be consumed as fresh or processed products such as sauce, paste, or juice. Tomato is a rich source of many substances including carotenoids (lycopene, carotenes, lutein, and phytoene), flavonoids, vitamins, amino acids, and other nutrients [19,20]. Previous studies have assessed the beneficial effects of tomato and their results have indicated a lot of useful properties such as antioxidant, anticancer, antimicrobial, anti-mutagenic, anti-inflammatory, anti-neurodegeneration, antiplatelet, and cardio-protective [21–23]. Most of the health benefits of tomato might be due to its anti-inflammatory and antioxidant properties [18]. Therefore, several randomized controlled trials (RCTs) have evaluated the effects of tomato intake on inflammatory mediators [24–30]. Although some investigations demonstrated that the consumption of tomato is associated with decreased levels of inflammatory mediators, others found unchanged levels of inflammatory markers [25,26,28–30]. Discrepancies among current evidence might be related to the differences in study design, different characteristics of studies populations, duration of supplementation, as well as different amounts of tomato used. In the systematic review and meta-analysis article, we included all published RCTs assessing the effect of tomato intake on CRP, IL-6, and TNF- α .

2. Methods

This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) statement [31].

2.1. Search strategy

In this systematic review and meta-analysis, two investigators searched independently PubMed, Scopus, ISI Web of Science, and Cochrane Library for studies listed from database inception to November 2021. The following MeSH and non-MeSH terms were used in our search strategy ("Inflammation" OR "C Reactive Protein" OR "CRP" OR "Tumor Necrosis Factor-alpha" OR "TNF alpha" OR "Tumor Necrosis Factor- α " OR "Tumor Necrosis Factor" OR "TNF- α " OR "Interleukin 6" OR "IL6") AND ("Lycopersicon esculentum" OR "tomato"). The search was not restricted to publication time, study

design, and language. In order not to miss any relevant publications, we also analyzed reference lists of relevant articles.

2.2. Study selection

The search results were imported into a bibliographic database and duplicates were removed automatically for accelerating the process of screening citations (EndNote X6; Thomson Reuters, New York). After removing duplicate citations, two independent individuals screened titles and abstracts to identify articles of interest. Subsequently, full texts of related articles were obtained and reviewed. Articles were included if they met all of the following criteria: (a) designed as RCTs (parallel or cross-over); (b) performed on adults (aged ≥ 18 years); (c) included participants randomized to tomato or control group; (d) circulating CRP, IL-6, and TNF- α levels were reported; and (e) data reporting regarding the changes of mentioned outcomes from baseline. Articles were excluded if they had a concomitant intervention for which effects could not be separated; or were of less than 1 weeks' duration; or studies on patients with inflammatory diseases such as hepatitis C, inflammatory bowel disease, and arthritis. Articles published in languages other than English were also excluded. If duplicate publications from the same study were identified, the publication with the largest number of cases from the study was included. In addition, when the articles reported insufficient data, the authors of that article were contacted by e-mail to request missing information. Any disagreement was resolved by discussion, consensus, or arbitration by a third senior investigator.

2.3. Data extraction

Two authors performed literature searches independently, and they resolved discrepancies by consensus or discussion with a third author. Data abstracted from the eligible articles were the last name of the first author, publication year, location of the study, total sample size, individuals' characteristics (e.g., mean age, sex, and body mass index [BMI]), type of study population, duration of the intervention, and dose of intervention.

2.4. Quality assessment

The quality of qualified studies was measured by two independent investigators by using the Cochrane Collaboration modified risk of bias tool [32], in which the risk of bias in RCTs is assessed in seven domains, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Each trial is considered "high risk" if it contained methodological flaws that may have affected the results, "low risk" if the flaw was deemed inconsequential, and "unclear risk" if the information was insufficient to determine. In the event of a discrepancy, it was resolved by consensus or discussion.

2.5. Statistical analysis

We used Stata software (version 12.0; Stata Corporation, College Station, TX, USA) to perform the meta-analysis and statistical analysis. Mean change and standard deviation (SD) of outcomes were used for calculating pooled weighted mean difference (WMD). Also, Hedges' g [33] was used to calculate pooled effect size for TNF- α and IL-6. In the event of no reported SD of the mean difference, it was calculated as follows: $SD = \text{square root} [(SD \text{ pre-treatment})^2 + (SD \text{ post-treatment})^2 - (2 \times R \times SD \text{ pretreatment} \times SD \text{ post-treatment})]$. For trials that only reported standard error of the mean (SEM), SD was obtained using the following formula:

$SD = SEM \sqrt{n}$, where “n” is the number of subjects in each group. Since included RCTs were carried out in different settings, random-effect models were used to conduct all meta-analyses. The heterogeneity was assessed by using the I^2 statistic with a value of <25%, 26–50%, and >50% were considered as low, moderate, and high degrees of heterogeneity, respectively. To identify whether differences in study characteristics were potential contributors to heterogeneity, we performed subgroup analyses based on participants' mean age, health status, gender, and study duration. Rather, sensitivity analyses were performed, to explore the extent to which inferences might depend on a particular study or group of studies. We also assessed publication bias by Egger's regression asymmetry test. A *P* value <0.05 was accepted as statistically significant unless otherwise specified.

3. Results

Our search yielded 785 articles for an initial review. Following the removal of duplicates, 467 were retained. We excluded 455 irrelevant references by reading titles and abstracts. In the next step, 5 papers were excluded based on the full-text review. These

exclusions were due to the following reasons: administered tomato in combination with other components ($n = 4$), and study with an intervention period of less than one week ($n = 1$). As a result, a total of seven articles were identified as eligible for the present meta-analysis. The flow chart of studies is presented in Fig. 1.

3.1. Study characteristics

Details characteristics of the included trials are outlined in Table 1. In total, 465 participants were enrolled in selected articles. These studies were published between 2000 and 2020 and were carried out in Iran [30], New Zealand [26], Germany [27], Israel [29], Scotland [25], the Czech Republic [28], and Taiwan [24]. The mean age of the participants ranged from 23 to 62 years old. Four studies [25,26,28,29] included both male and female participants, two studies enrolled female subjects [24,30], and one study included only male participants [27]. The follow-up period ranged from 2 to 12 weeks. Included studies were carried out in various populations, including T2DM patients [26], patients with hypertension [28], overweight or obesity subjects [30], post-menopausal women [24], middle-aged subjects [25], and healthy participants [27,29].




Fig. 1. Flow diagram of literature selection process for the systematic review of randomized controlled trials investigating the effect of tomato intake on inflammatory biomarkers in adults.

Table 1

Summary characteristics of 7 randomized controlled trials identified in the current systematic review and meta-analysis assessing the effect of tomato intake on inflammatory biomarkers in adults.

First author (year)	Country	Sample size	Gender	Mean age (years)	Mean BMI (kg/m ²)	Duration (weeks)	Participant's health status	Intervention	Control	Outcomes
Upritchard et al. (2000)	New Zealand	28	Both	62	30	4	T2DM	500 ml/d of tomato juice	Placebo	CRP
Briviba et al. (2004) a	Germany	25	Male	34	NR	2	Healthy smokers	Tomato oleoresin extract capsules	Placebo	TNF- α
Briviba et al. (2004) b	Germany	30	Male	33	NR	2	Healthy non-smokers	Tomato oleoresin extract capsules	Placebo	TNF- α
Blum et al. (2007)	Israel	63	Both	45	29	4	Healthy volunteers	300 g/day tomatoes	Usual diet with tomatoes prohibited	CRP
Thies et al. (2012)	Scotland	157	Both	51	26	12	Middle-aged	High-tomato-based diet	Low in tomato-based foods	CRP, IL-6
Ghavipour et al. (2013)	Iran	104	Female	23	28	3	Overweight and obese	330 ml/d of tomato juice	Water	CRP, TNF- α , IL-6
Michalickova et al. (2019)	Czech Republic	26	Both	47	26	4	Hypertension	200 g/day of tomato fruit juice enriched with 1 g of ethanolic extract of whole tomato fruit	200 g/day tomato fruit juice	CRP
Yang et al. (2020)	Taiwan	32	Female	59	26	8	Post-menopausal	250 g/day of beefsteak tomatoes	Normal diet	CRP

BMI, body mass index; T2DM, type 2 diabetes mellitus; NR, not reported; CRP, c-reactive protein; TNF- α , tumor necrosis factor- α ; IL-6, interleukin 6.

3.2. Quality assessment

The Cochrane risk of bias checklist showed that most of the studies had high methodological quality. The details of quality assessment in individual studies are provided in Table 2.

3.3. Effect of tomato on C-reactive protein

Overall, six studies [24–26,28–30] evaluated the effect of tomato intake on CRP levels. Pooled effect size of articles indicated that tomato was not significantly effective on CRP (WMD: 0.13 mg/dL, 95% CI: -0.09 to 0.36; $P = 0.23$, $I^2 = 83.9\%$) (Fig. 2). To find sources of heterogeneity, subgroup analysis revealed that participants' gender ($I^2 = 0.0\%$, $P = 0.71$) and health status ($I^2 = 0.0\%$, $P = 0.55$) were the potential sources of heterogeneity. However, subgroup analysis based on gender, participants' mean age, health status, and study duration showed that the effect is not statistically significant in all subgroups (Table 3). In addition, findings from sensitivity analysis showed that none of the studies significantly influenced the overall effect.

3.4. Effect of tomato on tumor necrosis factor- α

Combining effect sizes from 2 trials [27,30] (3 treatment arms), we showed that tomato intake significantly decreases TNF- α .

(Hedges' $g = -0.45$; 95% CI -0.76, -0.13; $P = 0.005$) levels. No evidence of heterogeneity was detected among the trials based on I^2 index (0.0%) (Fig. 3). We could not perform subgroup analysis due to a lack of sufficient study. Excluding individual studies did not result in a significant change in the overall meta-analysis results.

3.5. Effect of tomato on interleukin 6

The effect of tomato intake on IL-6 was examined in 2 clinical trials [25,30]. Meta-analysis could not show any beneficial effect of tomato on IL-6 (Hedges' $g = -0.12$; 95% CI -0.36, 0.13; $P = 0.34$, $I^2 = 0.0\%$) (Fig. 4). We could not perform subgroup analysis due to a lack of sufficient study.

3.6. Publication bias

According to the Egger's regression asymmetry test, no effect of publication bias was observed for CRP ($P = 0.34$), TNF- α ($P = 0.17$), and IL-6 ($P = 0.21$).

4. Discussion

The present meta-analysis is an effort towards evaluating the importance of tomato intake in improving inflammation. The key findings of this study were that tomato intake had no significant

Table 2

Quality of included randomized controlled trials assessing the effect of tomato intake on inflammatory biomarkers in adults using the Cochrane risk of bias tool.

First author (year)	Random sequence generation	Allocation concealment	Blinding of participants, personnel	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting	Other sources of bias
Upritchard et al. (2000)	L	U	H	H	L	L	U
Briviba et al. (2004)	L	H	L	H	L	L	L
Blum et al. (2007)	L	H	H	U	L	L	U
Thies et al. (2012)	L	L	L	U	L	L	L
Ghavipour et al. (2013)	L	L	L	U	L	L	U
Michalickova et al. (2019)	L	L	L	L	L	L	U
Yang et al. (2020)	L	H	H	U	L	L	U

U, unclear risk of bias; L, low risk of bias; H, high risk of bias.




Fig. 2. Forest plot showing non-significant effect of tomato intake on C-reactive protein levels in adults. Values are weighted mean differences with 95% CIs determined with the use of random-effects models. The heterogeneity was assessed by using the I² statistic, and values > 50% were considered as substantial heterogeneity between studies.

Table 3

Subgroup analyses to assess the effect of tomato intake on serum CRP concentrations.

Sub-grouped by	No. of trials	Effect size ^a	95% CI	I ² (%)	P for heterogeneity
Participant's mean age					
<50 years	3	0.46	-0.06 to 0.98	92.8	<0.001
>50 years	3	0.04	-0.15 to 0.23	32.9	0.22
Duration					
≥8 weeks	2	-0.04	-0.32 to 0.39	64.6	0.09
<8 weeks	4	0.34	-0.06 to 0.74	89.4	<0.001
Gender					
Both	4	0.05	-0.02 to 0.12	0.0	0.71
Female	2	0.99	-1.56 to 3.53	96.5	<0.001
Health status					
Healthy	4	0.30	-0.15 to 0.74	90.1	<0.001
Non-healthy	2	0.04	-0.06 to 0.13	0.0	0.55

The heterogeneity was assessed by using the I² statistic, a value of <25%, 26–50%, and >50% were considered as low, moderate, and high degrees of heterogeneity, respectively.

^a Calculated by Random-effects model.

effect on IL-6 and CRP, but did yield significant reductions in TNF- α . Results of subgroup analysis regarding CRP revealed that subgroup analysis based on participant's mean age, gender, health status, and intervention duration could not change these results.

The calculated CI for the effect of tomato intake on CRP was very close to the significant increase threshold. Indeed, it may be because tomato is usually consumed in sauces and tomato paste forms. These products are usually processed. Moreover, the anti-inflammatory effects of tomato are usually due to its antioxidant compounds, which may be due to high processing, the antioxidant content of these products is reduced [34–36]. In addition, the lack of significant benefit of tomato intake on CRP and IL-6 was likely due to limited power, with only 6, and 2 studies for CRP and IL-6,

respectively. Indeed, the power of a meta-analysis strongly depends on the number of included studies. Another reason for the non-significant effect might be due to the short duration of studies.

Our results showed that tomato intake leads to a reduction in serum TNF- α concentrations compared with control. We did not conduct any sub-group analysis for TNF- α due to limited RCTs. Our results are in line with the previous trial. Ghavipour et al. [30] found that there was a significant decrease in the level of TNF- α in the group given tomato juice when a comparison was made with that of the control group. In addition, Kirkil et al. [37] have reported that lycopene supplementation can significantly lower TNF- α levels in patients with chronic obstructive lung disease. Furthermore, RISO et al. [38] have reported the beneficial effects of tomato drink on




Fig. 3. Forest plot showing significant effect of tomato intake on tumor necrosis factor- α levels in adults. Values are Hedges' g with 95% CIs determined with the use of random-effects models.




Fig. 4. Forest plot showing non-significant effect of tomato intake on interleukin 6 levels in adults. Values are Hedges' g with 95% CIs determined with the use of random-effects models.

the production of inflammatory mediators such as TNF- α in young healthy volunteers. In another study, TNF- α was reduced during treatment with tomato juice in people who had recently been diagnosed with metabolic syndrome [39]. This result supports the hypothesis behind the anti-oxidative and anti-inflammatory efficacy of tomato and indicates that tomato intake can be a promising adjuvant agent that can be used along with conventional medicine for mitigating inflammation [36,40]. However, this result was derived from a low number of studies and should be interpreted with caution. Hence, more studies are needed to confirm the above statement.

The exact mechanism for improving TNF- α levels is not yet clear; however, there are numerous beneficial nutrients in tomato that have antioxidant and anti-inflammatory properties, such as lycopene, carotenes, lutein, flavonoids, and vitamins [36,41]. Studies have shown that lycopene decreases the translocation of nuclear factor kappa B (NF- κ B), which leads to a decreased expression of TNF- α [30,42,43]. Tomato also contains other important nutrients including the antioxidants β -carotene and vitamin C. These nutrients have been shown to decrease inflammation via their probable redox-based effect on the inactivation of NF- κ B [30,44]. In addition, lycopene can improve serum TNF- α levels, by increasing the NO/cGMP levels, as well as decreasing the generation of reactive oxygen species and nitrotyrosine [45].

Although generally tomato is known as a safe vegetable without any serious adverse effects, several undesired side effects have been related to tomato and tomato-based products consumption. Some of the side effects reported in this area include allergic reactions, gastrointestinal problems, and diarrhea [44]. In addition, tomato, especially the sauce, has a strong flavor and can make its way into breast milk. This can make the baby uncomfortable and irritable [44,46].

Some limitations should be considered when interpreting our findings. The main limitations of this systematic review and meta-analysis include a limited number of studies, a small sample size, and study duration. Due to the small number of studies, we were unable to perform dose response analysis. Another limitation that might be considered is that only studies involving humans were included in this study. Furthermore, the included studies were heterogeneous concerning the study design and characteristics of patients. The results of most included studies were also not adjusted for confounding factors. In addition, specific differences in tomato type and genus were not assessed. Finally, we did not register the protocol of the current study on PROSPERO registry system due to the delay in processing the submitted protocols for studies outside the UK. This lack of registration might be a source of bias for this review. However, this meta-analysis was designed and performed according to the Cochrane guidelines.

5. Conclusions

Generally, the present meta-analysis showed that tomato intake has no significant effect on serum levels of CRP, and IL-6, but can reduce TNF- α significantly. The authors advocate that further, well-controlled, studies should be conducted to clarify the safety and efficacy of tomato intake on inflammatory biomarkers.

Author contribution

G.W and M.J.A carried out the concept, design, and drafting of this study. M.R AND M.S searched databases, screened articles and extracted data. G.W performed the acquisition, analysis, and interpretation of data. M.J.A critically revised the manuscript. All authors approved the final version of the manuscript. G.W and M.J.A are the guarantors of this study.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The authors have no conflict of interest to report.

Acknowledgements

The author acknowledges the support of the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University.

References

- [1] Kim PK, Deutschman CS. Inflammatory responses and mediators. *Surgical clinics* 2000;80:885–94.
- [2] Subramanian AK, Prabhakar R, Vikram NR, Dinesh SS, Rajeshkumar S. In vitro anti-inflammatory activity of silymarin/hydroxyapatite/chitosan nanocomposites and its cytotoxic effect using brine shrimp lethality assay. *J Popul Therapeutics and Clinical Pharmacology= Journal de la Therapeutique des Populations et de la Pharmacologie Clinique* 2022;28:e71–7.
- [3] Shacter E, Weitzman SA. Chronic inflammation and cancer. *Oncology* 2002;16:217–26. 29; discussion 30.
- [4] Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. *Curr Opin Pulm Med* 2009;15:303–7.
- [5] Patil V, Avhad A, Kulkarni A, Pandere K. High-sensitive C-reactive protein in patients with coronary artery disease. *J Nat Sci Biol Med* 2020;11:39.
- [6] Kumar A. Potential biomarkers to detect inflammation leading to coronary artery disease. *J Nat Sci Biol Med* 2020;11:1.
- [7] Banerjee P, Kumar T, Sarangi SC, Meetei UD, Devi AS, Kumar R. Anti-inflammatory potential of aqueous extract of *elsoltzia stachyodes* on experimental models of inflammation in rats. *J Nat Sci Biol Med* 2021;12:104.
- [8] Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart* 2004;90:464–70.
- [9] Tavakoly R, Arab A, Vallianou N, Clark CC, Hadi A, Ghaedi E, et al. The effect of *Nigella sativa* L. supplementation on serum C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. *Compl Ther Med* 2019;45:149–55.
- [10] Casas-Agustench P, Bulló M, Salas-Salvadó J. Nuts, inflammation and insulin resistance. *Asia Pac J Clin Nutr* 2010;19:124–30.
- [11] Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. *Exp Gerontol* 2004;39:687–99.
- [12] Askari G, Aghajani M, Salehi M, Najafgholizadeh A, Keshavarzpour Z, Fadel A, et al. The effects of ginger supplementation on biomarkers of inflammation and oxidative stress in adults: a systematic review and meta-analysis of randomized controlled trials. *J Herb Med* 2020;22:100364.
- [13] Cassani RSL, Fassini PG, Silvah JH, Lima CMM, Marchini JS. Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study. *Nutr J* 2015;14:1–8.
- [14] Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. *Expet Opin Drug Saf* 2009;8:669–81.
- [15] Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. *Biochem Pharmacol* 2020;180:114147.
- [16] Speer H, D'Cunha NM, Alexopoulos NI, McKune AJ, Naumovski N. Anthocyanins and human health—a focus on oxidative stress, inflammation and disease. *Antioxidants* 2020;9:366.
- [17] Holt EM, Steffen LM, Moran A, Basu S, Steinberger J, Ross JA, et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. *J Am Diet Assoc* 2009;109:414–21.
- [18] Li N, Wu X, Zhuang W, Xia L, Chen Y, Wu C, et al. Tomato and lycopene and multiple health outcomes: umbrella review. *Food Chem* 2021;343:128396.
- [19] Viuda-Martos M, Sanchez-Zapata E, Sayas-Barberá E, Sendra E, Pérez-Álvarez J, Fernández-López J. Tomato and tomato byproducts. Human health benefits of lycopene and its application to meat products: a review. *Crit Rev Food Sci Nutr* 2014;54:1032–49.
- [20] Górecka D, Wawrzyniak A, Jędrusek-Golińska A, Dziedzic K, Hamulka J, Kowalczyński P, et al. Lycopene in tomatoes and tomato products. *Open Chem* 2020;18:752–6.
- [21] Abate M, Carlo LD, Cocco G, Cocco A, Sabatini E, Salini V. Oxidative stress and abnormal tendon sonographic features in elite soccer players (A pilot study). *Revista Brasileira de Ortopedia* 2021;56:432–7.
- [22] Kumar M, Tomar M, Bhuyan DJ, Punia S, Grasso S, Sa AGA, et al. Tomato (*Solanum lycopersicum* L.) seed: a review on bioactives and biomedical activities. *Biomed Pharmacother* 2021;142:112018.

- [23] Fuentes E, Trostchansky A, Reguengo LM, Junior MR, Palomo L. Antiplatelet effects of bioactive compounds present in tomato pomace. *Curr Drug Targets* 2021;22:1716–24.
- [24] Yang T-H, Chen YC, Ou T-H, Chien Y-W. Dietary supplement of tomato can accelerate urinary aMT6s level and improve sleep quality in obese postmenopausal women. *Clin Nutr* 2020;39:291–7.
- [25] Thies F, Masson LF, Rudd A, Vaughan N, Tsang C, Brittenden J, et al. Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. *Am J Clin Nutr* 2012;95:1013–22.
- [26] Upritchard JE, Sutherland W, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. *Diabetes Care* 2000;23:733–8.
- [27] Briviba K, Kulling SE, Möseneder J, Watzl B, Rechkemmer G, Bub A. Effects of supplementing a low-carotenoid diet with a tomato extract for 2 weeks on endogenous levels of DNA single strand breaks and immune functions in healthy non-smokers and smokers. *Carcinogenesis* 2004;25:2373–8.
- [28] Michalicková D, Belović M, Ilić N, Kotur-Stevuljević J, Slanař O, Šobajić S. Comparison of polyphenol-enriched tomato juice and standard tomato juice for cardiovascular benefits in subjects with stage 1 hypertension: a randomized controlled study. *Plant Foods Hum Nutr* 2019;74:122–7.
- [29] Blum A, Monir M, Khazim K, Peleg A, Blum N. Tomato-rich (Mediterranean) diet does not modify inflammatory markers. *Clin Invest Med* 2007:E70–4.
- [30] Ghavipour M, Saedisomeolia A, Djalali M, Sotoudeh G, Eshraghyan MR, Moghadam AM, et al. Tomato juice consumption reduces systemic inflammation in overweight and obese females. *Br J Nutr* 2013;109:2031–5.
- [31] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1–34.
- [32] Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons; 2019.
- [33] Hedges LV, Olkin I. *Statistical methods for meta-analysis*. Academic Press; 2014.
- [34] Ghadage S, Mane K, Agrawal R, Pawar V. Tomato lycopene: potential health benefits. *The Pharma Innovation Journal* 2019;8:1245–8.
- [35] Stoica R-M, Tomulescu C, Cășărică A, Soare M-G. Tomato by-products as a source of natural antioxidants for pharmaceutical and food industries—a mini-review. *Sci Bull Ser F Biotechnol* 2018;22:200–4.
- [36] Shah KK, Modi B, Lamsal B, Shrestha J, Aryal SP. Bioactive compounds in tomato and their roles in disease prevention. *Fundamental and Applied Agriculture* 2021;6:210–24.
- [37] Kırkı G, Muz MH, Sancaktar E, Kaman D, Şahin K, Küçük Ö. The effect of lycopene supplementation on chronic obstructive lung disease. *Helicobacter* 18:23.
- [38] Riso P, Visioli F, Grande S, Guarnieri S, Gardana C, Simonetti P, et al. Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress. *J Agric Food Chem* 2006;54:2563–6.
- [39] Tsitsimpikou C, Tsarouhas K, Kioukia-Fougia N, Skondra C, Fragkiadaki P, Papalexis P, et al. Dietary supplementation with tomato-juice in patients with metabolic syndrome: a suggestion to alleviate detrimental clinical factors. *Food Chem Toxicol* 2014;74:9–13.
- [40] Cheng HM, Koutsidis G, Lodge JK, Ashor AW, Siervo M, Lara J. Lycopene and tomato and risk of cardiovascular diseases: a systematic review and meta-analysis of epidemiological evidence. *Crit Rev Food Sci Nutr* 2019;59:141–58.
- [41] Chaudhary P, Sharma A, Singh B, Nagpal AK. Bioactivities of phytochemicals present in tomato. *J Food Sci Technol* 2018;55:2833–49.
- [42] Alharbi KS, Fuloria NK, Fuloria S, Rahman SB, Al-Malki WH, Shaikh MAJ, et al. Nuclear factor-kappa B and its role in inflammatory lung disease. *Chem Biol Interact* 2021;345:109568.
- [43] Khan UM, Sevindik M, Zarrabi A, Nami M, Ozdemir B, Kaplan DN, et al. Lycopene: food sources, biological activities, and human health benefits. *Oxid Med Cell Longev* 2021:2021.
- [44] Salehi B, Shariifi-Rad R, Sharopov F, Namiesnik J, Roointan A, Kamle M, et al. Beneficial effects and potential risks of tomato consumption for human health: an overview. *Nutrition* 2019;62:201–8.
- [45] Di Tomo P, Canali R, Ciavardelli D, Di Silvestre S, De Marco A, Giardinelli A, et al. β -Carotene and lycopene affect endothelial response to TNF- α reducing nitro-oxidative stress and interaction with monocytes. *Mol Nutr Food Res* 2012;56:217–27.
- [46] Bhowmik D, Kumar KS, Paswan S, Srivastava S. Tomato-a natural medicine and its health benefits. *J Pharmacogn Phytochem* 2012;1:33–43.

Effect of tomato consumption on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials

ORIGINALITY REPORT

18%
SIMILARITY INDEX

13%
INTERNET SOURCES

13%
PUBLICATIONS

9%
STUDENT PAPERS

MATCH ALL SOURCES (ONLY SELECTED SOURCE PRINTED)

1%
★ Rahele Sadat Montazeri, Somaye Fatahi, Mohammad Hassan Sohoul, Ahmed Abu - Zaid et al. "The effect of nigella sativa on biomarkers of inflammation and oxidative stress: A systematic review and meta - analysis of randomized controlled trials", Journal of Food Biochemistry, 2021
Publication

Exclude quotes On
Exclude bibliography On

Exclude matches < 15 words